An interventional study of Supervised Aerobic and Resistance Exercise in Obesity, Metabolically Healthy Obesity and Metabolically Unhealthy Obesity, sponsored by Harbin Sport University. Completed at 1 site in China. Open to male participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Harbin Sport University · Not applicable, Interventional, and Treatment
This study evaluated whether differences in the MC4R rs17782313 gene variant and metabolic health status were associated with different responses to a 12-week exercise and dietary intervention in adult men with obesity.
A total of 40 men aged 18 to 59 years with obesity participated in the study. At baseline, participants were classified as having metabolically healthy obesity or metabolically unhealthy obesity according to metabolic risk factors. All participants received the same supervised lifestyle intervention, which included aerobic exercise, resistance training, and an individualized energy-controlled diet.
Body weight, body composition, physical fitness, blood pressure, blood glucose, blood lipids, glycated hemoglobin, and fasting insulin were measured before and after the 12-week intervention. Blood samples were also collected for MC4R rs17782313 genotyping. The study examined whether changes after the intervention differed according to baseline metabolic phenotype and MC4R genotype.
This was a completed, single-center lifestyle intervention study involving adult men with obesity in Harbin, China.
Eligible participants were men aged 18 to 59 years with a body mass index of at least 28 kg/m2 and a waist circumference of at least 90 cm. At baseline, participants were classified as having metabolically healthy obesity or metabolically unhealthy obesity using criteria based on the National Cholesterol Education Program Adult Treatment Panel III.
Metabolically unhealthy obesity was defined as obesity accompanied by at least two of the following metabolic abnormalities: elevated blood pressure, elevated fasting blood glucose, elevated triglycerides, or reduced high-density lipoprotein cholesterol. Metabolically healthy obesity was defined as obesity accompanied by no more than one of these abnormalities.
All participants received the same 12-week supervised exercise and dietary intervention. The exercise program was conducted 5 days per week and consisted of aerobic exercise performed at approximately 60% to 70% of maximum heart rate and resistance exercise performed at approximately 40% to 60% of one-repetition maximum.
Daily energy intake was individualized according to standard body weight. The planned macronutrient distribution was approximately 50% to 60% of energy from carbohydrates, 15% to 20% from protein, and 20% to 30% from fat.
Anthropometric and body-composition assessments included body weight, body mass index, fat mass, body fat percentage, muscle mass, waist circumference, hip circumference, and waist-to-hip ratio. Physical fitness assessments included vital capacity, handgrip strength, vertical jump, push-ups, sit-ups, sit-and-reach flexibility, one-leg standing with eyes closed, choice reaction time, and back strength.
Physiological and biochemical assessments included resting heart rate, systolic and diastolic blood pressure, fasting blood glucose, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glycated hemoglobin, and fasting insulin. Measurements were conducted at baseline and after 12 weeks.
MC4R rs17782313 genotype and baseline metabolic phenotype were analytical stratification variables. They were not used to assign different interventions. The study evaluated changes from baseline to week 12 and examined whether intervention responses were associated with metabolic phenotype, MC4R genotype, or their interaction.
27 studies on the registry are indexed under Obesity, Metabolically Benign; 8 are open to participants now.
This study's enrollment of 40 is below the median of 60 across 17 interventional studies indexed under Obesity, Metabolically Benign.
Browse Obesity, Metabolically Benign studies →Harbin Sport University is the lead sponsor of 2 studies on the registry; none are open to participants now.
Compared within Obesity, Metabolically Benign, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received the same 12-week supervised lifestyle intervention consisting of aerobic exercise, resistance training, and an individualized energy-controlled diet. Participants were subsequently classified according to baseline metabolic phenotype and MC4R rs17782313 genotype for subgroup analyses; these classifications did not determine intervention assignment.
Behavioral: Supervised Aerobic and Resistance Exercise
Participants completed a 12-week supervised exercise program conducted 5 days per week. The aerobic exercise component consisted of 10 sessions per week, approximately 90 minutes per session, performed at 60% to 70% of maximum heart rate. Activities included aerobic exercise classes, boxing-style aerobic exercise, step exercise, cycling, interval-based exercise, and other structured aerobic activities. Heart rate was monitored during training. The resistance exercise component consisted of 5 sessions per week, approximately 90 minutes per session, performed at approximately 40% to 60% of one-repetition maximum. Exercises included machine-based circuit training, core training, and strength and body-shaping exercises. Training was supervised by qualified instructors.
Change From Baseline in Body Weight at Week 12
Body weight was measured in kilograms using a calibrated electronic scale, with participants wearing light clothing and no shoes. Change in body weight was calculated as the body weight measured at Week 12 minus the baseline body weight.
Time frame: Baseline and Week 12
Ran from Mar 2025 to primary completion in Jun 2025, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Obesity, Metabolically Benign →
Harbin Sport University